Perceptive Advisors LLC Decreased Alnylam Pharmaceuticals (ALNY) Holding by $5.95 Million

June 17, 2018 - By Marie Mckinney

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) LogoInvestors sentiment decreased to 1.4 in Q1 2018. Its down 0.63, from 2.03 in 2017Q4. It turned negative, as 25 investors sold ALNY shares while 67 reduced holdings. 43 funds opened positions while 86 raised stakes. 89.26 million shares or 1.02% less from 90.18 million shares in 2017Q4 were reported. Comml Bank Of Montreal Can reported 0.01% stake. Apg Asset Management Nv has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Metropolitan Life Insur Communications owns 5,988 shares. Parametric Port Assocs Ltd Liability Corp reported 0.01% stake. 10,500 were accumulated by Spark Inv Management Limited Co. Ibm Retirement Fund owns 2,577 shares or 0.06% of their US portfolio. Hanseatic Mngmt Serv holds 0.59% or 5,154 shares in its portfolio. Macquarie Limited holds 0.01% or 42,884 shares in its portfolio. Canada Pension Plan Investment Board owns 3,921 shares. Vantage Investment Advisors Llc stated it has 655 shares or 0.02% of all its holdings. Advisory Research accumulated 2,922 shares. 4,213 were reported by M&T National Bank & Trust. Ny State Common Retirement Fund has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Signaturefd Ltd Co, a Georgia-based fund reported 26 shares. Vanguard Incorporated reported 0.04% stake.

Since January 4, 2018, it had 0 insider purchases, and 11 insider sales for $39.55 million activity. CLARKE JOHN K sold $1.50 million worth of stock. SCHIMMEL PAUL sold $4.17M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, March 13. The insider SHARP PHILIP A sold 15,000 shares worth $2.24M. Shares for $12.67 million were sold by Vaishnaw Akshay. $2.57 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by Ausiello Dennis A. On Wednesday, March 14 Greene Barry E sold $5.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 38,460 shares.

Joseph Edelman decreased its stake in Alnylam Pharmaceuticals (ALNY) by 3.76% based on its latest 2018Q1 regulatory filing with the SEC. Perceptive Advisors Llc sold 50,000 shares as the company’s stock declined 18.72% with the market. The hedge fund run by Joseph Edelman held 1.28 million shares of the health care company at the end of 2018Q1, valued at $152.54 million, down from 1.33 million at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Alnylam Pharmaceuticals for a number of months, seems to be less bullish one the $10.84B market cap company. The stock increased 0.69% or $0.74 during the last trading session, reaching $107.8. About 685,801 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 43.86% since June 17, 2017 and is uptrending. It has outperformed by 31.29% the S&P500.

Perceptive Advisors Llc, which manages about $2.09B and $3.57 billion US Long portfolio, upped its stake in Iovance Biotherapeutics Inc by 1.39 million shares to 6.16 million shares, valued at $104.14M in 2018Q1, according to the filing. It also increased its holding in Biohaven Pharmaceutical Hldg Co L by 2.67 million shares in the quarter, for a total of 2.93M shares, and has risen its stake in Dbv Technologies S A.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 earnings per share, down 27.61 % or $0.37 from last year’s $-1.34 per share. After $-1.41 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28 % negative EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Biotech industry group criticized for party featuring topless dancers” on June 13, 2018, also Seekingalpha.com with their article: “Alnylam’s lumasiran shows positive effect in Phase 1/2 PH1 study” published on June 08, 2018, Seekingalpha.com published: “Eidos Therapeutics files for initial public offering” on May 25, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” published on June 08, 2018 as well as Nasdaq.com‘s news article titled: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.” with publication date: June 03, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 11 analysts covering Alnylam Pharma (NASDAQ:ALNY), 6 have Buy rating, 1 Sell and 4 Hold. Therefore 55% are positive. Alnylam Pharma had 22 analyst reports since January 7, 2018 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Monday, April 23 report. The firm has “Buy” rating given on Monday, March 12 by FBR Capital. The stock has “Buy” rating by BMO Capital Markets on Thursday, February 8. The rating was maintained by FBR Capital with “Buy” on Friday, February 16. Credit Suisse maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Tuesday, March 13. Credit Suisse has “Outperform” rating and $154 target. Jefferies maintained the shares of ALNY in report on Monday, January 8 with “Buy” rating. FBR Capital maintained the shares of ALNY in report on Wednesday, May 23 with “Buy” rating. FBR Capital maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Wednesday, March 28. FBR Capital has “Buy” rating and $20000 target. The rating was maintained by Piper Jaffray on Thursday, March 22 with “Buy”. Morgan Stanley maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Monday, May 7. Morgan Stanley has “Equal-Weight” rating and $107 target.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: